Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia |
| |
Authors: | Kyoung-Sae Na Won-Hyoung Kim Han-Yong Jung Seong Gon Ryu Kyung Joon Min Ki-Chang Park Yong-Sik Kim Jin-Sang Yoon Yong Min Ahn Chul-Eung Kim |
| |
Institution: | 1. Department of Psychiatry, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea;2. Department of Psychiatry, Inha University Hospital, Incheon, Republic of Korea;3. Department of Psychiatry, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea;4. Department of Psychiatry, Chung-Ang University Hospital, Seoul, Republic of Korea;5. Department of Psychiatry, Wonju Christian Hospital, Wonju, Republic of Korea;6. Department of Psychiatry, Dongguk University Ilsan Hospital, Ilsan, Republic of Korea;g Department of Psychiatry, Chonnam National University, Gwangju, Republic of Korea;h Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea |
| |
Abstract: | ObjectiveMetabolic syndrome and antipsychotic medications are associated with inflammation. This study investigated the relationship between inflammation and metabolic syndrome in patients with schizophrenia. It also examined the effects of paliperidone extended release (ER) treatment on metabolic parameters.MethodsData were analyzed from schizophrenic patients who participated in a multi-center, open-label, non-comparative clinical trial. Anthropomorphic measurements (i.e., weight, waist circumference, and blood pressure) were assessed along with fasting laboratory values, including white blood cell (WBC) count, glucose, high-density lipoprotein, and triglycerides.ResultsAmong the 225 patients at baseline, the group with the highest WBC count displayed a 5.9-fold risk for metabolic syndrome compared with that of the lowest group. An increase of 103 WBCs/μL was associated with a 1.4-fold increased risk for metabolic syndrome. After 24 weeks of treatment with paliperidone ER, significant increases were observed in waist circumference and body weight. Changes in WBC count were positively correlated with changes in waist circumference.ConclusionsSchizophrenic patients with high levels of inflammation should be carefully monitored for metabolic syndrome. Moreover, strategies to reduce inflammation and obesity may prevent metabolic syndrome in patients with schizophrenia who take atypical antipsychotic medication. |
| |
Keywords: | ER extended release WBC white blood cell HDL high-density lipoprotein SGA second-generation antipsychotic CATIE Clinical Antipsychotic Trials of Intervention Effectiveness CRP C-reactive protein BMI body mass index DSM-IV Diagnostic and Statistical Manual for Mental Disorders fourth edition NCEP: ATP III National Cholesterol Education Program Adult Treatment Panel III WHO World Health Organization TG triglyceride |
本文献已被 ScienceDirect 等数据库收录! |
|